Moderna, Inc. Income Tax Expense
Moderna, Inc. (MRNA) reported Income Tax Expense of $15.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-07-31
- Moderna, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was $15.00M, a 114.29% increase year-over-year.
- Moderna, Inc. income tax expense (benefit) for the quarter ending 2026-03-31 was $9.00M, a 28.57% increase year-over-year.
- Moderna, Inc. income tax expense (benefit) for the quarter ending 2025-12-31 was $27.00M.
- Moderna, Inc. income tax expense (benefit) for the quarter ending 2025-09-30 was $13.00M, a 62.50% increase year-over-year.
- Moderna, Inc. income tax expense (benefit) for fiscal 2025 was $54.00M.
- Moderna, Inc. income tax expense (benefit) for fiscal 2024 was -$46.00M, a 105.96% decline from fiscal 2023.
- Moderna, Inc. income tax expense (benefit) for fiscal 2023 was $772.00M, a 36.36% decline from fiscal 2022.
- Moderna, Inc. income tax expense (benefit) for fiscal 2022 was $1.21B, a 12.00% increase from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 9 month as first filed | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.00M 10-Q · filed 2026-07-31 | $24.00M 10-Q · filed 2026-07-31 | $51.00M derived: sum of 3 quarters · filed 2026-07-31 | $64.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $9.00M 10-Q · filed 2026-05-01 | $36.00M derived: sum of 2 quarters · filed 2026-05-01 | $49.00M derived: sum of 3 quarters · filed 2026-05-01 | $56.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $40.00M derived: sum of 2 quarters · filed 2026-02-20 | $47.00M derived: sum of 3 quarters · filed 2026-07-31 | $54.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $13.00M 10-Q · filed 2025-11-06 | $20.00M derived: sum of 2 quarters · filed 2026-07-31 | $27.00M 10-Q · filed 2025-11-06 | -$37.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $7.00M 10-Q · filed 2026-07-31 | $14.00M 10-Q · filed 2026-07-31 | -$50.00M derived: sum of 3 quarters · filed 2026-07-31 | -$42.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $7.00M 10-Q · filed 2026-05-01 | -$57.00M derived: sum of 2 quarters · filed 2026-05-01 | -$49.00M derived: sum of 3 quarters · filed 2026-05-01 | -$49.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$64.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$56.00M derived: sum of 2 quarters · filed 2026-02-20 | -$56.00M derived: sum of 3 quarters · filed 2026-02-20 | -$46.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $8.00M 10-Q · filed 2025-11-06 | $8.00M derived: sum of 2 quarters · filed 2025-11-06 | $18.00M 10-Q · filed 2025-11-06 | -$129.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-01 | $10.00M 10-Q · filed 2025-08-01 | -$137.00M derived: sum of 3 quarters · filed 2026-02-20 | $1.53B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $10.00M 10-Q · filed 2025-05-01 | -$137.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.53B derived: sum of 3 quarters · filed 2026-02-20 | $1.17B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$147.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.52B derived: sum of 2 quarters · filed 2026-02-20 | $1.16B derived: sum of 3 quarters · filed 2026-02-20 | $772.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $1.67B 10-Q · filed 2024-11-07 | $1.30B derived: sum of 2 quarters · filed 2024-11-07 | $919.00M 10-Q · filed 2024-11-07 | $1.11B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$369.00M 10-Q · filed 2024-08-01 | -$753.00M 10-Q · filed 2024-08-01 | -$563.00M derived: sum of 3 quarters · filed 2025-02-21 | -$389.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | -$384.00M 10-Q · filed 2024-05-02 | -$194.00M derived: sum of 2 quarters · filed 2025-02-21 | -$20.00M derived: sum of 3 quarters · filed 2025-02-21 | $257.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $190.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $364.00M derived: sum of 2 quarters · filed 2025-02-21 | $641.00M derived: sum of 3 quarters · filed 2025-02-21 | $1.21B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $174.00M 10-Q · filed 2023-11-03 | $451.00M derived: sum of 2 quarters · filed 2023-11-03 | $1.02B 10-Q · filed 2023-11-03 | $1.56B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $277.00M 10-Q · filed 2023-08-03 | $849.00M 10-Q · filed 2023-08-03 | $1.39B derived: sum of 3 quarters · filed 2024-02-23 | $1.61B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $572.00M 10-Q · filed 2023-05-04 | $1.11B derived: sum of 2 quarters · filed 2024-02-23 | $1.33B derived: sum of 3 quarters · filed 2024-02-23 | $1.62B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $542.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $761.00M derived: sum of 2 quarters · filed 2024-02-23 | $1.04B derived: sum of 3 quarters · filed 2024-02-23 | $1.08B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $219.00M 10-Q · filed 2022-11-03 | $502.00M derived: sum of 2 quarters · filed 2022-11-03 | $541.00M 10-Q · filed 2022-11-03 | $543.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $283.00M 10-Q · filed 2022-08-03 | $322.00M 10-Q · filed 2022-08-03 | $324.00M derived: sum of 3 quarters · filed 2023-02-24 | $325.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $39.00M 10-Q · filed 2022-05-04 | $41.00M derived: sum of 2 quarters · filed 2023-02-24 | $42.00M derived: sum of 3 quarters · filed 2023-02-24 | $42.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $3.00M derived: sum of 2 quarters · filed 2023-02-24 | $3.00M derived: sum of 3 quarters · filed 2023-02-24 | $3.00M 10-K · filed 2023-02-24 | $2.55M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $1.00M 10-Q · filed 2021-11-04 | $864.00K 10-Q · filed 2020-10-30 | $1.00M derived: sum of 2 quarters · filed 2021-11-04 | $1.00M 10-Q · filed 2021-11-04 | $1.08M 10-Q · filed 2020-10-30 | $526.00K derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $148.00K 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2021-08-05 | $214.00K 10-Q · filed 2020-08-06 | -$474.00K derived: sum of 3 quarters · filed 2022-02-25 | -$652.00K derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | $66.00K 10-Q · filed 2020-05-07 | -$474.00K derived: sum of 2 quarters · filed 2022-02-25 | -$652.00K derived: sum of 3 quarters · filed 2022-02-25 | -$976.00K derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$652.00K derived: sum of 2 quarters · filed 2022-02-25 | -$976.00K derived: sum of 3 quarters · filed 2022-02-25 | -$1.00M 10-K · filed 2022-02-25 | -$695.00K 10-K · filed 2020-02-27 | |||
| 2019-09-30 | -$178.00K 10-Q · filed 2020-10-30 | -$502.00K derived: sum of 2 quarters · filed 2020-10-30 | -$526.00K 10-Q · filed 2020-10-30 | -$358.00K derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | -$324.00K 10-Q · filed 2020-08-06 | -$348.00K 10-Q · filed 2020-08-06 | -$180.00K derived: sum of 3 quarters · filed 2021-02-26 | -$180.00K derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | -$24.00K 10-Q · filed 2020-05-07 | $144.00K derived: sum of 2 quarters · filed 2021-02-26 | $144.00K derived: sum of 3 quarters · filed 2021-02-26 | $302.00K derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $168.00K derived: sum of 2 quarters · filed 2021-02-26 | $326.00K derived: sum of 3 quarters · filed 2021-02-26 | $326.00K 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 | $158.00K derived: sum of 2 quarters · filed 2019-11-06 | $158.00K 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $158.00K 10-Q · filed 2019-08-08 | $158.00K 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$80.00K 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $1.04M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |